🔎 Trials Near Me

Akèy › Lukemi lenfositè kwonik › Montana › Billings

Etid klinik pou Lukemi lenfositè kwonik nan Billings, MT

7 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan ak bò kote Billings (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Ap rekriteFaz 3
  • Billings Clinic Cancer Center, Billings
Laj 65 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07321652

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
  • Billings Clinic Cancer Center, Billings
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Ap rekriteFaz 3
  • Billings Clinic Cancer Center, Billings
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT04269902

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

Ap rekriteFaz 3
  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 5433), Billings
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT05947851

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Ap rekriteFaz 3
  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0052), Billings
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06136559

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Ap rekriteFaz 3
  • St. Vincent Frontier Cancer Center, Billings
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05254743

Etid Lukemi lenfositè kwonik nan lòt vil

Lòt etid nan Billings

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.